Client News

Roquefort Therapeutics PLC – Director/PDMR Shareholding
Home / Client News / Roquefort Therapeutics PLC – Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Ajan Reginald, Chief Executive Officer has purchased ordinary shares in the Company, as detailed below:


Number of Ordinary Shares

Average Price Paid Per Share

Total Consideration Paid


7.06 pence



Following the above purchase of shares, Ajan Reginald holds an interest in 11,663,051 Company ordinary shares.



Director/PDMR Shareholding – 10:00:10 26 Jun 2023 – ROQ News article | London Stock Exchange


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This